Mersana Therapeutics Past Earnings Performance
Past criteria checks 0/6
Mersana Therapeutics's earnings have been declining at an average annual rate of -33.4%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 1.4% per year.
Key information
-33.4%
Earnings growth rate
-9.5%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 1.4% |
| Return on equity | -465.2% |
| Net Margin | -465.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Mersana Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 37 | -172 | 60 | 0 |
| 30 Sep 23 | 41 | -197 | 64 | 0 |
| 30 Jun 23 | 39 | -215 | 66 | 0 |
| 31 Mar 23 | 32 | -213 | 63 | 0 |
| 31 Dec 22 | 27 | -204 | 57 | 0 |
| 30 Sep 22 | 12 | -208 | 53 | 0 |
| 30 Jun 22 | 6 | -194 | 48 | 0 |
| 31 Mar 22 | 2 | -183 | 42 | 0 |
| 31 Dec 21 | 0 | -170 | 37 | 0 |
| 30 Sep 21 | 0 | -150 | 32 | 0 |
| 30 Jun 21 | 0 | -127 | 28 | 0 |
| 31 Mar 21 | 1 | -106 | 24 | 0 |
| 31 Dec 20 | 1 | -88 | 22 | 0 |
| 30 Sep 20 | 1 | -75 | 20 | 0 |
| 30 Jun 20 | 2 | -70 | 19 | 0 |
| 31 Mar 20 | 1 | -67 | 18 | 0 |
| 31 Dec 19 | 42 | -28 | 17 | 0 |
| 30 Sep 19 | 43 | -34 | 17 | 0 |
| 30 Jun 19 | 45 | -35 | 17 | 0 |
| 31 Mar 19 | 49 | -30 | 17 | 0 |
| 31 Dec 18 | 11 | -64 | 16 | 0 |
| 30 Sep 18 | 13 | -56 | 15 | 0 |
| 30 Jun 18 | 17 | -46 | 14 | 0 |
| 31 Mar 18 | 16 | -43 | 12 | 0 |
| 31 Dec 17 | 18 | -39 | 10 | 0 |
| 30 Sep 17 | 26 | -23 | 9 | 0 |
| 30 Jun 17 | 23 | -22 | 8 | 0 |
| 31 Mar 17 | 26 | -16 | 8 | 0 |
| 31 Dec 16 | 25 | -14 | 7 | 0 |
| 31 Dec 15 | 10 | -16 | 5 | 0 |
Quality Earnings: 0M4 is currently unprofitable.
Growing Profit Margin: 0M4 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0M4 is unprofitable, and losses have increased over the past 5 years at a rate of 33.4% per year.
Accelerating Growth: Unable to compare 0M4's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0M4 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: 0M4 has a negative Return on Equity (-465.18%), as it is currently unprofitable.